Chronic Kidney Disease (CKD) is a major global public health problem which progresses slowly and get worse over time. It is the 8th leading cause of death in United States, and is characterized by kidney damage and reduced kidney function. According to National Kidney Foundation, approximately 26 millions of adults are living with Chronic Kidney Disease and millions of others are at increased risk of developing Chronic Kidney Disease. More than 20 million patients suffer from moderate (stages 3 or 4) or severe (stage 5) forms of CKD. This condition is very common among people aged 70 years or older.

Prevalence of CKD is increasing with an increase in prevalence of diabetes, hypertension, and cardiovascular disease in aging population. Several conditions such as diabetes, high blood pressure, Polycystic Kidney Disease, Polynephrities, Glomerulonephritis, Malformation, and Vasicourorectal conditions leads to development of Chronic Kidney Disease. Recently, researchers found that patients with Chronic Kidney Disease are at high risk of developing urinary tract, viral-related, digestive and breast cancers. Patients experience cognitive impairment, dementia, sleep disturbance, pain, emotional and physical dysfunction. It also increases the chances of developing cardiovascular disease and bone-metabolism disorders.

Treatment of Chronic kidney disease mainly focuses on controlling pathologic manifestations of Chronic Kidney Disease such as Hyperphosphatemia, Hypocalcemia, cardiovascular complications and Anemia. Ravaldee was approved in 2016 by USFDA for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease. Auryxia was approved for the treatment of hyperphosphatemia in patients with chronic kidney disease. Major players such as Celgene Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Astellas Pharma and Boehringer Ingelheim are developing drugs which are expected to be launch in upcoming years.

Several factors such as increasing prevalence of Chronic Kidney Disease worldwide, increasing aging population, increasing number of patients with diabetes, rising demand for advanced diagnostics and therapeutics improvement in healthcare infrastructure, might help in launch of emerging therapies in coming years. This provides hope of stimulating market growth of Chronic Kidney Disease in the coming years.

Insight by:
Diksha Wadhwa
Associate Analyst

 DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating their decision-making. DelveInsight also serves as a knowledge partner for business strategy and market research. We provide comprehensive analytical reports across various therapeutic indications. DelveInsight has a database of 3000+ high-quality analytical reports